EUbOPEN

What EUbOPEN does

EUbOPEN (Enabling and Unlocking Biology in the OPEN) is a publicly funded research consortium launched in 2019 under the Innovative Medicines Initiative 2 (IMI2) Joint Undertaking, with the stated mission of creating open-access chemical biology tools for the global drug discovery community. The consortium operates as a public-private partnership spanning 22 partner institutions across Europe and North America, including five EFPIA pharmaceutical companies (Boehringer Ingelheim, Laboratoires Servier, Pfizer, Bayer, Takeda) and leading academic and infrastructure centers (University of Oxford, University of Toronto, Karolinska Institutet, McGill University, ETH Zurich, University of Dundee, University of North Carolina at Chapel Hill, Goethe University Frankfurt, Georg-Speyer-Haus, Leiden University Medical Center, EBI, Fraunhofer CIMD, Diamond Light Source, KTH, and OICR). Operational and website coordination is administered by the Centre for Medicines Discovery at the University of Oxford.

The consortium's core deliverables are an open-access chemogenomic library of approximately 5,000 well-annotated compounds covering roughly 1,000 different proteins, at least 100 high-quality open-access chemical probes, and validated protocols for at least 20 primary patient-derived cell-based assays spanning colorectal cancer, inflammatory bowel disease, liver fibrosis, and multiple sclerosis. Supporting infrastructure includes the EUbOPEN Data Gateway (gateway.eubopen.org), collaborative access to Diamond XChem crystallographic fragment screening at Diamond Light Source, the interactive Human Ion Channelome Ligands database, chemical handles, antibodies, and a Target 2035-aligned webinar series. All artifacts are released under CC-BY licensing with no commercial pricing.

EUbOPEN does not generate commercial revenue. Its €65.8 million five-year budget is funded through IMI2 Joint Undertaking grant agreement No 875510, combining European Union Horizon 2020 funds with cash and in-kind contributions from EFPIA member companies and Associated Partners (KTH, OICR, Diamond Light Source, McGill). Its go-to-market is community-led: dissemination occurs through the Data Gateway, peer-reviewed publications in journals including Nature Communications and JACS, the Target 2035 webinar series, and the partner network.

Name

EUbOPEN

Legal name

EUbOPEN (Enabling and Unlocking Biology in the Open)

Website

https://eubopen.org

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

51–100 employees

Short description

EUbOPEN is an IMI2-funded research consortium producing open-access chemogenomic libraries, chemical probes, and patient-derived tissue assay protocols for the global biomedical research community, operated by 22 academic and industry partners under CC-BY licensing with no commercial revenue.

Ownership category

akta.pro rank

Product category

Drug Discovery Research Tools

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

akta.pro secondary industries

Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL), Cell-Based & Potency Assays (Bioassays) (HLAGADAH)

Keywords

• Chemical biology research
• Chemogenomic library
• Chemical probes
• Drug discovery tools
• Tissue assay protocols

Headquarters

HQ city

Oxford

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Infrastructure

Revenue model

1. Public Research Funding: EUbOPEN is funded through the Innovative Medicines Initiative 2 (IMI2) Joint Undertaking with a total budget of 65.8 million euros, comprising grants from IMI and cash/in-kind contributions from EFPIA companies and Associated Partners. The consortium does not generate commercial revenue.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

EUbOPEN is an IMI-funded research consortium that creates and disseminates open-access chemical biology research tools, including a chemogenomic library of approximately 5,000 well-annotated compounds covering roughly 1,000 proteins, at least 100 high-quality chemical probes, validated patient-derived tissue assay protocols, chemical handles, and a Data Gateway portal. All outputs are provided free of charge under CC-BY licensing to academic and pharmaceutical researchers worldwide to accelerate drug discovery on the druggable genome.

Product overview

EUbOPEN is an Innovative Medicines Initiative (IMI) funded consortium that functions as a platform for open-access chemical biology research tools. The consortium offers a suite of interconnected products including an open-access chemogenomic library of approximately 5,000 compounds targeting roughly 1,000 proteins, high-quality open-access chemical probes (with a goal of synthesizing at least 100), and standardized tissue assays for profiling these compounds across disease areas including colorectal cancer, inflammatory bowel disease, liver fibrosis, and multiple sclerosis. Additional offerings include chemical handles, validated protocols for patient-derived assays, a Data Gateway portal, and collaborative access to Diamond XChem fragment screening services at Diamond Light Source. The consortium also maintains the Human Ion Channelome Ligands database as a specialized chemogenomic resource. These products collectively enable researchers to explore disease biology and identify biomarkers and novel drug targets.

Differentiator

Problem solved

Functional benefit

Brands

• Target 2035: Initiative to produce a chemical probe for every human protein by 2035
• Donated Chemical Probes (DCP)
• Diamond XChem Fragment Screening
• Data Gateway

Products and services

• Open-Access Chemical Probes

Quantifiable outcome

• 65.8M euro investment enabling open science drug discovery tools
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

25 partnerships are on record, tiered core and minor.

• Diamond Light Source (XChem Fragment Screening)coreTechnology or Integration · 7 June 2023Provides crystallographic fragment screening access for EUbOPEN targets; hosted joint webinars on accessing the facility
• KTH Royal Institute of TechnologyminorOthersIMI Associated Partner contributing to the consortium
• Ontario Institute for Cancer Research (OICR)minorOthersIMI Associated Partner contributing to the consortium
• Diamond Light SourceminorOthersIMI Associated Partner providing access to crystallographic fragment screening facilities
• McGill UniversityminorOthersIMI Associated Partner contributing to the consortium
• Structural Genomics ConsortiumcoreStrategic or Co-development PartnerKey research partner leading chemical probe development and target characterization efforts
• University of OxfordcoreStrategic or Co-development PartnerLead academic partner hosting Centre for Medicines Discovery; administers consortium website and coordination
• University of TorontocoreStrategic or Co-development PartnerAcademic partner contributing to chemogenomics and tissue assay development
• Karolinska InstitutetcoreStrategic or Co-development PartnerAcademic partner contributing tissue assay expertise, particularly in liver fibrosis and multiple sclerosis models
• University of North Carolina at Chapel HillcoreStrategic or Co-development PartnerAcademic partner in the consortium
• Goethe University FrankfurtcoreStrategic or Co-development PartnerAcademic partner contributing to chemical probe and assay development
• McGill UniversitycoreStrategic or Co-development PartnerAcademic partner in the consortium
• University of DundeecoreStrategic or Co-development PartnerAcademic partner contributing to the consortium
• European Bioinformatics Institute (EBI)coreTechnology or IntegrationProvides data infrastructure and integration for the EUbOPEN Data Gateway
• ETH ZurichcoreStrategic or Co-development PartnerAcademic partner contributing to the consortium
• Georg-Speyer-HauscoreStrategic or Co-development PartnerAcademic partner in the consortium
• Leiden University Medical CentercoreStrategic or Co-development PartnerAcademic partner in the consortium
• Boehringer IngelheimcoreStrategic or Co-development PartnerEFPIA member company contributing industry expertise and in-kind resources
• Laboratoires ServiercoreStrategic or Co-development PartnerEFPIA member company contributing industry expertise and in-kind resources
• PfizercoreStrategic or Co-development PartnerEFPIA member company contributing industry expertise and in-kind resources
• BayercoreStrategic or Co-development PartnerEFPIA member company contributing industry expertise and in-kind resources
• Takeda Pharmaceutical CompanycoreStrategic or Co-development PartnerEFPIA member company contributing industry expertise and in-kind resources
• Target 2035 InitiativecoreStrategic or Co-development PartnerGlobal initiative to produce a chemical probe for every human protein by 2035; EUbOPEN is a key contributor and co-host of joint webinars
• FAIRplusminorStrategic or Co-development PartnerCollaboration on making EUbOPEN data FAIR (Findable, Accessible, Interoperable, Reusable)
• Rosalind Franklin InstituteminorStrategic or Co-development PartnerNew partnership announced to expand consortium capabilities

Scale indicators6 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Open Targets: Public-private partnership (EMBL-EBI, GSK, MSD, Sanger) focused on systematic target identification and validation using genomic and chemical data; directly overlaps EUbOPEN's target validation mission and open-data philosophy.
• TB Alliance: Global non-profit drug development partnership coordinating open-access R&D for tuberculosis treatments; analogous consortium model with industry/academic partners and shared infrastructure focus.
• Medicines for Malaria Venture: Product development partnership that funds and coordinates open, collaborative drug discovery for malaria; comparable in PPP structure, multi-partner governance, and output orientation toward validated research tools.
• Critical Path Institute: Neutral, non-profit consortium catalyzing drug development through shared data standards and tools across industry, regulators, and academia; comparable as a PPP that produces shared research infrastructure.
• Structural Genomics Consortium: Open-science consortium producing chemical probes and protein reagents for the druggable genome; EUbOPEN's core research partner and the most directly comparable open-access chemical biology platform globally.

Broad incumbents

• Broad Institute Center for the Development of Therapeutics: Major academic drug discovery center producing chemical probes, screening libraries, and target validation capabilities at scale; broader portfolio but directly comparable technology stack and mission.
• NIH NCATS Chemical Genomics Center: Operates the former Molecular Libraries Program providing open-access screening and chemical probe resources for the research community; closely aligned public-sector peer in probe generation and chemogenomics.

Others

• European Bioinformatics Institute (EMBL-EBI): Provides the data infrastructure powering EUbOPEN's Data Gateway and ChEMBL-linked chemogenomic resources; relevant as the enabling bioinformatics peer rather than a direct competitor.
• Fraunhofer CIMD: EUbOPEN partner offering translational drug discovery capabilities and chemical biology infrastructure; comparable as an adjacent German/European research infrastructure provider.

Emerging players

• Rosalind Franklin Institute: UK research institute developing new chemical biology and structural biology technologies; recent EUbOPEN partner with overlapping capability in novel probe and assay development.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks3 records

Key highlights6 records

Customer concentration

• Xx.com/eubopen
• LinkedInlinkedin.com/company/eubopen

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EUbOPEN